Mechanisms of immunomodulation and cytoprotection conferred to pancreatic islet by human amniotic epithelial cells

Fanny Lebreton
University of Geneva Medical Centre: Universite de Geneve Faculte de Medecine
https://orcid.org/0000-0002-3175-0205

Charles H. Wassmer
University of Geneva Medical Centre: Universite de Geneve Faculte de Medecine

Kevin Bellofatto
University of Geneva Medical Centre: Universite de Geneve Faculte de Medecine

Lisa Perez
University of Geneva Medical Centre: Universite de Geneve Faculte de Medecine

Véronique Othenin-Girard
Geneva University Hospitals: Hopitaux Universitaires Geneve

Begoña Martinez de Tejada
Geneva University Hospitals: Hopitaux Universitaires Geneve

Marie Cohen
University of Geneva Medical Centre: Universite de Geneve Faculte de Medecine

Ekaterine Berishvili (✉ ekaterine.berishvili@unige.ch)
https://orcid.org/0000-0002-7969-1937

Research

Keywords: Human amniotic epithelial cells, Immunomodulation, Cytoprotection, Pancreatic islets, Pro-inflammatory cytokines

DOI: https://doi.org/10.21203/rs.3.rs-236761/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Inhibiting pro-inflammatory cytokine activity can reverse inflammation mediated dysfunction of islet grafts. Human amniotic epithelial cells (hAECs) possess regenerative, immunomodulatory and anti-inflammatory properties. We hypothesized that hAECs could protect islets from cellular damage induced by pro-inflammatory cytokines. To verify our hypothesis hAECs monocultures, rat islets (RI), or RI-hAEC co-cultures where exposed to a pro-inflammatory cytokine cocktail (Interferon γ: IFN-γ, Tumor necrosis factor α: TNF-α and Interleukin-1β: IL-1β). The secretion of anti-inflammatory cytokines and gene expression changes in hAECs and viability and function of RI were evaluated. The expression of non-classical Major Histocompatibility Complex (MHC) class I molecules by hAECs cultured with various IFN-γ concentrations were assessed. Exposure to the pro-inflammatory cocktail significantly increased the secretion of the anti-inflammatory cytokines IL6, IL10 and G-CSF by hAECs, which was confirmed by upregulation of IL6, and IL10 gene expression. HLA-G, HLA-E and PDL-1 gene expression was also increased. This correlated with an upregulation of STAT1, STAT3 and NF-κB1 gene expression levels. RI co-cultured with hAECs maintained normal function after cytokine exposure compared to RI cultured alone, and showed significantly lower apoptosis rate. Our results show that exposure to pro-inflammatory cytokines stimulates secretion of anti-inflammatory and immunomodulatory factors by hAECs through the JAK1/2 – STAT1/3 and the NF-κB1 pathways, which in turn protects islets against inflammation-induced damages. Integrating hAECs in islet transplants appears as a valuable strategy to achieve to inhibit inflammation mediated islet damage, prolong islet survival, improve their engraftment and achieve local immune protection allowing to reduce systemic immunosuppressive regimens.

Background

Islet transplantation is a minimally invasive approach allowing to restore glycemic control in diabetic patients (1). However, long-term function of the graft and steady metabolic control remain a challenge due to ischemic, inflammatory, allogenic and autoimmune attacks causing damages to the transplanted islets (2). Significant number of islets are destroyed immediately after transplantation, due to the onset of inflammatory reaction (3). Inflammatory islet damage is mediated at least partially by pro-inflammatory cytokines, such as interferon-γ (IFN-γ), tumor necrosis factor-α, (TNF-α) and interleukin 1β (IL-1β) (4). When exposed to these pro-inflammatory cytokines, both rodent and human islet cells lose ability to respond to glucose stimulation and undergo apoptosis (5). Moreover, these cytokines recruit and activate macrophages, thus aggravating the inflammatory response (3). It has been shown that decreasing cytokine expression, and inhibiting cytokine and macrophage activity significantly improves the function of transplanted islets (6). Therefore, minimizing inflammation at the transplant site has been considered a major strategy to prolong islet graft function and maintain long-term insulin independence (7).

Among several approaches proposed to improve islet transplantation outcomes, islet co-transplantation with accessory non islet-derived cells showed promising experimental results (8). Mesenchymal stem cells (MSCs) have been the main cell types used to protect islets from inflammation injury due to their anti-inflammatory and/or immunomodulatory properties. Several studies have shown that co-culturing
islets with MSCs derived from different sources (adipose tissue or bone marrow) protected islets from inflammation and enhanced their revascularization, function and engraftment (9). Over the last decades, MSCs have been intensively used in regenerative medicine, especially for the treatment of inflammatory and degenerative disorders (10). However, harvesting MSCs is an invasive procedure and obtaining sufficient number of cells is not always possible, as cell numbers and properties decline with donor age. Tumor originicity of MSCs is also a concern (11). Among the several cell sources available for tissue regeneration, human amniotic epithelial cells (hAECs) have been recognized as valid candidates (12). They reside on the amniotic membrane and together with other placental cells are believed to participate to the development of materno-fetal tolerance during pregnancy (13). hAECs express nuclear markers of pluripotency and surface markers of embryonic stem cells (ESC) such as SSEA-4, OCT-4 and SOX-2(14).

When grown in specialized media, hAECs differentiate toward all three germ layers (15). Furthermore, hAECs exhibit anti-inflammatory and immunomodulatory properties, are easily accessible, inexpensive and do not bear the risk of tumorigenicity (13). Several in vitro and in vivo studies have demonstrated pleiotropic immune regulatory activities of hAECs, mediated by complex mechanisms that inhibit the function of different cell subpopulations of innate and adaptive immunity. AECs express low levels of major histocompatibility complex (MHC) class I surface antigens, while MHC class II antigens (16), or the costimulatory molecules CD80, CD86, CD40, and CD154 are not expressed, even in the presence of IFN-γ (16, 17). hAECs inhibit local activation/migration of neutrophils and macrophages and suppress the activation and cytotoxic action of T-cells in both mixed lymphocyte reaction and mitogen-induced proliferation assays (16). Expression and secretion of several mediators of localized immune suppression including TGFβ, HLA-G, IL-6, IL-10 and Fas-L have been identified in isolated hAECs (18, 19).

Our group has studied the effect of hAECs on islet cells. We have recently shown that either combining hAECs with dissociated islet cells in insulin-secreting organoids or shielding of whole islets with hAECs protects islet cells against hypoxia-induced damage in vitro and improves β cell engraftment and vascularization after transplantation in diabetic mice (20, 21). These characteristics indicate that hAECs may be capable of creating a microenvironment conducive to sustained islet graft survival.

In this study, we have examined the cytoprotective effect of isolated hAECs on islets exposed to pro-inflammatory cytokines and established some of the underlying mechanisms.

**Methods**

**Human amniotic epithelial cells (hAECs) isolation and characterization**

hAECs were isolated as previously described (21) Briefly, the amniotic membrane was mechanically peeled from the underlying chorion, washed in Hanks’ Balanced Salt Solution (HBSS, ThermoFisher Scientific, Reinach, Switzerland), cut into small pieces and trypsinised (0.25% Trypsin/EDTA, ThermoFisher Scientific) to release cells. Dispersed hAECs were collected by centrifugation, seeded at a density 2x10^5 cells/cm^2 and cultured in hAEC culture medium consisting in DMEM/F-12 medium (ThermoFisher Scientific,) supplemented 2 mmol/l L-Glutamin, 100 U/ml Penicillin and 0.1 mg/ml
Streptomycin (1% (v/v) of a L-Glutamin-Penicillin-Streptomycin stock solution from Sigma-Aldrich), 1 mmol/l sodium pyruvate (Sigma-Aldrich), 1% (v/v) MEM NEAA 100X (ThermoFisher Scientific), 0.1% fungin (InvivoGen, San Diego, CA), 10% fetal bovine serum (FBS; Merk Millipore, Zug, Switzerland), 0.05 mmol/l 2-mercaptoethanol (ThermoFisher Scientific), 10 ng/ml human recombinant epidermal growth factor (EGF, Sigma-Aldrich).

Confluent cells were trypsinised (0.05% Trypsin/EDTA, ThermoFisher Scientific) and characterized by flow cytometry (FC; figure 1.A). Cells were washed in FC buffer (PBS-0.1 % BSA supplemented with 0.01% sodium azide) and incubated for 30 minutes at 4°C with the following antibodies: FITC-conjugated anti-human CD105 (clone 266), BV421-conjugated anti-human CD326 (clone EBA-1), PerCP-Cy5.5 conjugated anti-SSEA4 (clone MC813-70) (1:50 dilution; all from BD Biosciences, Allschwil, Switzerland), PE-Cy7 conjugated anti-human CD90 (clone 5E10) (1:100 dilution, BD Biosciences), PE-conjugated anti-human HLA-E (clone 3D12) and APC-conjugated anti-human HLA-G (clone 87G) (1:20 dilution, Biolegend, London, UK) antibodies. Controls were stained with isotype-matched irrelevant antibody to evaluate non-specific binding to target cells. Cells were analyzed on a Gallios cytometer (Beckman Coulter, Indianapolis, Indiana, US) using Kaluza Analysis software from Beckman Coulter (Version 1.5.20365.16139). The percentage of positive cells for the different markers was assessed on a gate set on hAECs by using forward- and side-scatter analysis during the acquisition of data, followed by doublets and Drag7-positive (dead) cells exclusion. Representative histograms were plotted using FlowJo software (version 10.6.1, BD Biosciences). hAECs cultured on collagen-coated coverslips were fixed in 4% paraformaldehyde (PFA), rinsed and permeabilized. For histological characterization, after two washes, unspecific binding sites were blocked and samples were stained with the following primary antibodies: monoclonal anti-SSEA-4 (1:75 dilution, clone MC813, Abcam, Cambridge, UK), polyclonal anti-Oct4 (1:200 dilution, Abcam, Cambridge, UK) and monoclonal anti-human HLA-G (1:50 dilution, clone 4H84, BD Biosciences). The secondary antibodies were Alexa 555 anti-mouse or anti-rabbit antibodies (1:300 dilution, ThermoFisher Scientific). Stained cells were mounted with aqueous mounting medium containing DAPI (Fluoroshield Mounting Medium with DAPI, Abcam). Images were captured using a Zeiss Axioscan.Z1 slide scanner (Zeiss, Feldbach, Germany).

**Rat pancreatic islets isolation**

Animal experiments were performed under protocols reviewed and approved by the Geneva Veterinary authorities and the University of Geneva Institutional Animal Care and Use Committee.

Ten-week old male Lewis rats (LEW/OrlRj; Janvier Labs, Le Genest St-Isle, France) were used for pancreatic islet isolation. Rat pancreatic islets were isolated as previously described (22, 23), purified by Ficoll density centrifugation and cultured in islet culture medium consisting of DMEM (ThermoFisher Scientific) supplemented with 10% (v/v) FBS (ThermoFisher Scientific), 1 mmol/l sodium pyruvate, 11mmol/l glucose (Bichsel, Interlaken, Switzerland), 0.05 mmol/l 2-mercaptoethanol, 2 mmol/l L-Glutamine, 100 U/ml Penicillin and 0.1 mg/ml Streptomycin for one day prior to be used in co-culture experiments.
Exposure of hAECs to IFN-γ

hAECs were seeded onto 25cm² tissue culture-treated flasks at a density of 17'500 cells/cm². Culture media were replaced the next day and cells were exposed to various concentrations of recombinant murine IFN-γ for 48 h. Untreated hAEC served as controls. Supernatants from treated and untreated hAECs were analyzed to detect secreted anti- and pro-inflammatory factors. hAEC phenotype were assessed by FC analysis.

Exposure of hAECs: Islet co-culture to pro-inflammatory cytokines

hAECs were thawed and added (1.0×10⁶ cells) to a 100 mm tissue culture-treated dish with 500 islet equivalents (IEQ) in a total volume of 10 mL hAEC culture medium. Rat islet (RI) and hAECs monocultures were used as controls. After 24 h incubation, a pro-inflammatory cytokine cocktail consisting of 100 U/mL recombinant murine Interferon-gamma (IFN-γ), 800 U/mL recombinant human Tumor Necrosis Factor-alpha (TNF-α) and 50 u/mL recombinant human Interleukine-1 beta (IL-1β) was added to 10 ml of culture medium for an additional 48 h (figure 3.A).

All cytokines were obtained from Peprotech (London, UK).

Analysis of culture supernatant for soluble cytoprotective factors

Culture supernatants from hAECs monocultures were sampled before and after cytokine exposure and stored at -20°C until further assessment. Qualitative detection of secreted anti- and pro-inflammatory factors (IL6, IL10, TNF-α, G-CSF and TGF-β1) in the culture media was performed using the commercial Multi-Analyte ELISArray assay MEH003A from Qiagen (Courtaboeuf, France). Released IL6, IL10 and G-CSF were quantified using Quantikine ELISA for human IL-6, IL-10 and G-CSF (R&D Systems, Abingdon, UK), according to manufacturer instructions.

Cell apoptosis assay

RI (100 IEQ), hAECs (2x10⁵ cells) and RI + hAECs (2x10⁵ hAECs+100 IEQ) cultured in 35 mm² petri dishes with or without cytokines were washed with PBS and cytoplasmic histone-associated DNA fragments were extracted and quantified using the Cell Death Detection ELISA kit from Roche (Sigma-Aldrich) according to manufacturer instructions.

Islet functional assay

RI and RI + hAECs cultured with or without cytokines were assessed in duplicates for glucose stimulated insulin secretion. After a 1 hour pre-incubation in Krebs–Ringer buffered HEPES (pH 7.4) with 0.1% (w/v) BSA (KRB) at 37°C, islets and cells were successively incubated for 1 hour at 37°C in KRB solutions containing glucose at low (2.8 mmol/l) or high (16.7 mmol/l) concentration. Total insulin content was extracted using acid-ethanol solution. Supernatants were collected after each incubation time, insulin concentration was determined by ELISA (Mercodia, Uppsala, Sweden) and normalized to the total insulin
content of the corresponding lysates. Islet responsiveness to glucose was defined as the ratio of insulin secretion in high glucose to insulin secretion in low glucose solution, hereafter referred to as the stimulation index (SI).

**Real-Time quantitative Polymerase Chain Reaction**

RNA was extracted from hAECs monocultures (10⁶ cells in 10 cm² petri dishes) or RI+hAEC co-cultures using the RNeasy minikit (Qiagen, Courtaboeuf, France). cDNAs were synthesized by reverse-transcription using the GoScript™ Reverse Transcription Kit (Promega, Dübendorf, Switzerland). RT-qPCR was performed using the Takyon No-Rox SYBR Core Kit blue dTTP (Eurogentec, Liège, Belgium), or the Taqman Fast Advance Master Mix (Thermofisher Scientific). Primers used for amplification were purchased from Microsynth (Balgach, Switzerland) and Thermofisher Scientific and targeted the following genes: human *IL4, IL6, IL8, IL10, HLA-G, HLA-E, STAT1, STAT3, JAK1, JAK2, NFKB1*, and rat *Bcl2* and *Nfkb1*. Gene expression values were normalized to the housekeeping genes human *RPLP0*, human *EIF2B1*, rat *Rplp1* and rat *Actb*, and calculated with the comparative cycle threshold Ct method (2^ΔCt method). All primer forward and reverse sequences are detailed in table 1.

**Statistical analysis**

Continuous and categorical variables are presented as mean ± SEM. Comparisons between groups were performed with unpaired two-tailed Student’s *t*-test or one-way / two-way ANOVA with Tukey’s or Sidak’s post-hoc test wherever appropriate. All statistical analyses were performed with Prism software 7.02 (GraphPad, La Jolla, CA, USA), and *p < 0.05* was considered statistically significant.

**Results**

**Characterization of hAECs**

hAECs isolated following a standardized protocol (figure 1.A) were characterized using FC (figure 1.B). hAECs were positive for CD326, CD90, CD105, SSEA-4, HLA-G and HLA-E. Expression of the pluripotency and immunomodulatory markers was confirmed by immunohistological staining (figure 1.C), showing the cytosolic localization of SSEA-4 and HLA-G, while OCT4 was found in both the cytoplasm and the nucleus. These findings are in line with our and other’s previous findings (13, 21).

**IFN-γ augments immunomodulatory potential of hAECs**

In the initial experiment, we have assessed whether exposure to IFN-γ at various concentrations had an impact on immunomodulatory and other markers expressed by hAECs (Figure 2).

FC analysis demonstrated that HLA-G expression was not affected by low concentrations of IFN-γ, but was significantly increased by both 1000 U/mL and 2000 U/mL (46.1 ± 6.5% and 48.1 ± 4.8% respectively) IFN-γ treatments compared to untreated cells (13.1 ± 1.9%) (*p=0.0048* and *p=0.0011* respectively). Interestingly, the increase in HLA-G expression was correlated with time in culture (Figure
2.B). Expression of HLA-E was significantly increased in primed cells. More than 90% of treated cells were expressing HLA-E on their surface and the lowest concentration of the cytokine was sufficient to affect this marker (p<0.0001) (Figure 2.C).

Treated cells expressed CD90, CD326 and SSEA-4 without alterations. In contrast, IFN-γ had an impact on the expression of CD105 (Figure 2.D) in a dose-dependent manner. Although expression of CD105 remained unchanged at low IFN-γ concentrations, exposure of cells to higher concentrations (1000 U/ml and 2000 U/mL) significantly increased CD105 expression compared to untreated controls (Figure 2.D).

*In vitro exposure to pro-inflammatory cytokines enhances anti-inflammatory and immunomodulatory properties of hAEC*

β cell death associated with nonspecific inflammation is mainly mediated by production of pro-inflammatory cytokines such as IFN-γ, TNF-α and IL-1β (4, 24). In order to examine whether these inflammatory cytokines would have an impact on anti-inflammatory and immunomodulatory potential of hAECs, cells were treated with the three-cytokine cocktail. Detailed experimental design is shown in Figure 3.A.

Basal levels of cytokines secreted by hAECs (control) were measured in the supernatants after 24h of culture. Supernatants from hAECs exposed to cytokines were analyzed after 24h and 48h of incubation. Although baseline levels of IL6, TNFα and TGF-β1 were quite low in control samples, a significant increase in IL6 concentration was detected in supernatants from primed cells both at 24h and 48h after the cytokines treatment (p<0.0001 vs control at both time points). TNFα and G-CSF concentration were also elevated (data not shown).

IL6 and G-CSF concentrations were also measured by ultra-sensitive ELISA assay (Figure 3.B). Concentrations of IL6 in the culture medium of treated cells were significantly higher compared to untreated controls both at 24h (411.2 ± 19.3 pg/mL, vs 193.7 ± 61.01 pg/mL, p=0.0039) and 48h (390.6 ± 5.9 pg/mL, vs 180.6 ± 62.9 pg/mL, p=0.0010). Although IL10 was detectable in the control samples and its concentration increased between 24h and 48h of culture, no significant effect of cytokines exposure was observed. In contrast, G-CSF secretion was significantly elevated both after 24h (23.7 ± 11.2 pg/mL vs 6.3 ± 0.07 pg/mL, p=0.0182) and 48h (28.8 ± 7.4 pg/mL vs 6.2 ± 0.2 pg/mL, p=0.0017) compared to basal level, as well as in comparison with untreated culture at 48h (28.8 ± 7.4 pg/mL and 6.2 ± 0.2 pg/mL respectively, p=0.0041).

To reveal the mechanisms behind the anti-inflammatory action of hAECs, gene expression changes were evaluated (figure 3.C). Pro-inflammatory cytokines did not evidently affect IL4 gene expression. In contrast, exposure of cells to pro-inflammatory conditions significantly upregulated IL6 and IL8 genes (113.9 ± 69.7 and 81.6 ± 73.2 fold, respectively). Moreover, two-fold upregulation of IL10 was detected compared to control. Similarly, mRNA levels of HLA-G, HLA-E and PD-L1 were significantly upregulated.
Changes in expression of genes involved in intracellular signaling cascade were also studied. STAT1, STAT3 and NF-κB1 were significantly overexpressed in treated hAECs compared to controls, with a 4.9 ± 0.69, 2.06 ± 0.3 and 1.83 ± 0.2 fold increase respectively. JAK1 and JAK2 exhibited a trend to slightly increase.

These data indicate that exposure of primary hAECs to inflammatory cytokines, IFN-γ, TNF-α and IL-1β promotes their anti-inflammatory properties and increases expression of immunomodulatory molecules.

**hAECs co-cultured with islets prevent cytokine induced islet cell apoptosis and preserve islet function under exposure to cytokines**

To investigate whether anti-inflammatory factors secreted by hAECs in response to pro-inflammatory cytokines would be able to protect islets against inflammation-induced damage, RI + hAECs co-cultures were exposed to the three-cytokine cocktail (figure 3.A). The islet cell damage was assessed by quantification of cytoplasmic histone-associated DNA fragments in culture lysates. RI exposed to cytokines showed significant increase in the apoptotic rate compared to untreated controls (1.64 ± 0.7 A.U. and 0.18 ± 0.07 A.U. respectively, p=0.0041). In contrast, islets co-cultured with hAECs, had apoptosis rate similar to intact controls (0.19 ± 0.05 A.U.) (Figure 3.D). These results correlated with a significant upregulation of the pro-apoptotic gene NF-κB1 (2.11 ± 0.39 fold, p= 0.008) and down-regulation of the anti-apoptotic gene BCL2 (0.38 ± 0.19 fold, p= 0.014) in RI after cytokine exposure compared to untreated RI. In contrast, significant upregulation of BCL2 and downregulation of NF-κB1 mRNA levels were detected in RI+hAECs cocultures exposed to cytokines (Figure 3.E).

To assess islet responsiveness to glucose stimulation, static incubation assay was performed. Islets without cytokine exposure exhibited a glucose induced stimulation index of 2.1±0.09 (n=3). Exposure to cytokines significantly altered islet function with a stimulation index of 0.83 ± 0.11 (Figure 3.F). In contrast, RI co-cultured with hAECs maintained a normal insulin secretion (1.66 ± 0.02).

**Discussion**

In this study, we demonstrate that exposing hAECs to inflammatory conditions increases their anti-inflammatory and immunomodulatory properties by affecting their phenotype and function. Moreover, we show that hAECs are capable to protect islets from inflammatory damage through the modulation of the inflammatory response. To the best of our knowledge, this is the first study that reports the effect of factors secreted by human hAECs on islet cell viability and function under inflammatory conditions in vitro.

We have previously reported that hAECs protect islet cells from ischemic injury in vitro via HIF-1α pathway (25). Furthermore, we showed that hAECs facilitate larger β-cell mass engraftment and improve in vivo function via acceleration of revascularization and reestablishment of cell-to-matrix contacts (20, 21). In addition to these cytoprotective effects, hAECs have the potential to protect islets from immune destruction by inhibiting lymphocyte proliferation (26). However, underlying mechanisms for these
protective actions still need to be elucidated. Integrating the findings of this study with the relevant literature, we propose a mechanistic model for the enhancement of anti-inflammatory and immunomodulatory properties of hAECs and the protection they confer to islets grafts (Figure 4).

Our results showed that hAECs exposed to pro-inflammatory cytokines exhibit increased secretion of anti-inflammatory factors, in particular IL6, IL8, IL10 and G-CSF. This was associated with overexpression of the transcription factor NF-κB1, suggesting an involvement of the NF-κB1 pathway due to the activation of IFN-γ, TNF-α and IL-1β receptors, as shown in Figure 4 (left part).

NF-κB is a multi-functional transcription factor, activated under pro-inflammatory stimuli and involved in various important biological processes including survival, inflammation, apoptosis and immune regulation (27). At early stages of pregnancy release of IL-1β and TNF-α from endometrial cells activates NF-κB in fetal cells, which in turn facilitates trophoblast invasion and angiogenesis. At the time of delivery, NF-κB secreted by amnion has a leading role in stimulating uterine contraction during labor by inducing in particular pro-inflammatory gene expression (28). NF-κB is also linked to the activation of several anti-apoptotic genes, adhesion molecules and growth factors (29). The pro-survival role of NF-κB has been attributed to the production of IL6 and IL8 (30). Interestingly, our results demonstrating absence of apoptosis in hAECs exposed to pro-inflammatory conditions, correlated with elevation of IL6 and IL8. This can be explained by activation of NF-κB mediated anti-apoptotic signaling.

The granulocyte colony-stimulating factor (G-CSF) is a potent regulator of granulocyte production that is produced in response to the inflammatory stimuli by different hematopoietic and non-hematopoietic cells including placental tissue cells(31). Among its many biological effects, G-CSF has a cytoprotective effect on islets cells (32). During pregnancy, G-CSF regulates embryo implantation and development via activation of the STAT3 signaling pathway(33). Furthermore, it was shown that G-CSF enhances MMP-2 activity and VEGF secretion in a human trophoblast cell line through activation of PI3K/Akt and Erk signaling pathways (34). Finally, G-CSF has been shown to have modulatory effects on immune cells. In particular, it suppresses pro-inflammatory cytokines in peripheral blood mononuclear cells, induces tolerant dendritic cells (DCs), increases IL4 but reduces IFN-γ in vivo(35), and promotes tolerance to the graft in islet transplantation experiments (36).

Interestingly, we have observed increased G-CSF secretion by hAECs in response to pro-inflammatory cytokine exposure accompanied by upregulation of STAT1 and STAT3 genes, indicating involvement of G-CSF in the protective action of hAECs through the activation of STAT signaling.

Along with secretion of cytoprotective factors by primed hAEC, we observed a significant increase of immunomodulatory molecule expression. HLA-G expression increased with time, as well as in high concentrations of IFN-γ. In contrast, marked increase in HLA-E expression was detected in response to low concentrations of IFN-γ (10 U/mL). Expression of these markers is known to be regulated by pro-inflammatory conditions (37, 38). Mechanistically, HLA-E expression is upregulated by IFN-γ, mediated by an upstream STAT1 binding site (37). HLA-G expression is mainly regulated by IFN-γ through the JAK/STAT pathway, involving in particular STAT1 (39).
and STAT3, which suggests that overexpression of HLA-E and HLA-G is due to the activation of the IFNγ – JAK 1/2 – STAT1/3.

Expression of HLA-class Ib molecules, such as HLA-G and HLA-E, and anti-inflammatory molecules by hAECs exerts in turn a protective effect on islets against damage induced by inflammation. Indeed, in the immediate post-transplantation period, islets are exposed to a highly inflammatory liver microenvironment (2), where pro-inflammatory cytokines, such as IFN-γ, TNF-α and IL-1β, are largely produced in response to ischemia reperfusion injury. These factors trigger β-cell apoptosis through NF-κB activation and endoplasmic reticulum stress (5) and impair insulin secretion through an excessive nitric oxide production affecting both ATP production by the mitochondria (Figure 4, right part, bold arrows) (40) and gap junction coupling between β-cells (41). Infiltration of leukocytes and macrophages during the peri-transplantation period, as well as recruitment of neutrophils, macrophages, Kupffer cells and CD4+ and CD8+ lymphocytes in the later stages of engraftment also contribute to islet cell death (3).

In this context, the increased expression of HLA-G and HLA-E by hAECs under pro-inflammatory conditions appear of particular interest to protect islet grafts from inflammation-induced damage.

HLA-G and HLA-E belong to the nonclassical HLA Ib family, characterized by low polymorphism and immunomodulatory properties. HLA-G is mainly expressed by placental and embryonic tissues and participates in development of foeto-maternal tolerance (42). In contrast, HLA-E is ubiquitously expressed and acts as an inhibitor of NK-cell driven lysis (43). Both molecules induce immune tolerance by inhibiting DC proliferation, switching T lymphocytes to a Treg phenotype, inhibiting CD8+ and CD4+ T cells (13) and modulating the release of cytokines from mononuclear cells (MNCs) (16) (Figure 4, bottom panels).

In addition, the immunomodulatory cytokines secreted by hAECs play a major role in suppressing inflammatory responses (Figure 4, right panel, dashed lines). Expression of IL10 by amniotic cells has been well described, and is known to inhibit the release of pro-inflammatory mediators by monocytes and macrophages, reducing antigen presentation, and inhibiting CD4+ and CD8+ T cell differentiation and proliferation as well as B cell recruitment (13). Increased levels of IL10 have been associated to improved islet survival and function in allotransplantation experiments while artificial upregulation of IL10 expression decreased alloreactivity to human islets and increased rat islet allograft survival (44, 45). IL6 is known to exert anti-inflammatory actions through STAT3 activation, and has been shown to protect islets and β-cells from pro-inflammatory cytokine-induced apoptosis and loss of function in vitro. Moreover, improved survival and graft function was demonstrated after transplantation of islets pretreated with IL6 through the overexpression of anti-apoptotic genes (46). In addition, IL6 improves β-cell survival by stimulating autophagy and reducing cell oxidative stress (47). Finally, IL6 exerts angiogenic effects by inducing expression of vascular endothelial growth factor (VEGF) in various cell lines (48).

Another factor overexpressed in cytokine-exposed hAECs is IL8, a neutrophil-recruiting cytokine, which is also known to promote endothelial cell proliferation (49) and angiogenesis (50) and thus contribute to improved vascularization (21).
Conclusion

In conclusion, our results demonstrate that anti-inflammatory and immunomodulatory potential of hAECs significantly augments when exposed to inflammatory cytokines in vitro, this in turn has a cytoprotective effect on pancreatic islets in a co-culture set-up. Taken together, this indicates that integration of hAECs in islet transplants could be a valuable strategy to: i) inhibit inflammation mediated islet damage; ii) achieve local immune protection of islets after transplantation; iii) prolong islet survival and engraftment, which currently limits the application of allogeneic islet transplantation.

Abbreviations

bFGF: basic fibroblast growth factor

G-CSF: granulocyte-colony stimulating factor 3

EGF: epithelial growth factor

EIF2B1: eukaryotic translation initiation factor 2B subunit alpha

ER: endoplasmic reticulum

ESC: embryonic stem cell

hAECs: human amniotic epithelial cells

HAM: human amniotic membrane

HB-EGF: heparin binding epithelial growth factor

HLA-G: human leucocyte antigen-G

HLA-E: human leucocyte antigen-E

IGF-1: insulin growth factor-1

IL4: Interleukin 4

IL6: Interleukin 6

IL8: Interleukin 8

IL10: Interleukin 10

ILT2: Immunoglobulin-like transcript 2

ILT4: Immunoglobulin-like transcript 4
JAK1: Janus kinase 1
JAK2: Janus kinase 2
KIR2DL4: Killer cell immunoglobulin-like receptor 2DL4
MSC: mesenchymal stem cells
NF-κB1: nuclear factor kappa B subunit 1
NK: Natural killer cells
NO: nitric oxyde
OCT-4: octamer-binding transcription factor 4
RI: rat islets
RPLP0: ribosomal protein lateral stalk subunit P0
SSEA-4: Stage-specific embryonic antigen-4
SOX-2: SRY (sex determining region Y)-related HMG-box gene 2
STAT1: signal transducer and activator of transcription 1
STAT3: signal transducer and activator of transcription 3
Tregs: Regulatory T lymphocytes
VEGF: vascular endothelial growth factor

Declarations

Ethics approval and consent to participate

Experiments using human tissues were covered by protocols approved by the state of Geneva Ethical Committee (Commission Cantonale d’Ethique de la Recherche – CCER). Amniotic membranes were harvested from term healthy placentas of women undergoing elective cesarean section at the Geneva University Hospitals. Informed written consent was obtained from each donor prior to tissue collection.

Animal experiments were performed under protocols reviewed and approved by the Geneva Veterinary authorities and the University of Geneva Institutional Animal Care and Use Committee.

Consent for publication

N/A
Availability of data and materials

The data that support the findings of this study are available from the corresponding author, E.B., upon reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

This work is supported by grants from the European Foundation for the Study of Diabetes (EFSD), the European Commission (Horizon 2020 Framework Program; VANGUARD grant 874700), the Juvenile Diabetes Research Foundation (JDRF; grant 3-SRA-2020-926-S-B) and the Shota Rustaveli National Science Foundation (grant FR-19-19760).

Author contributions

Fanny Lebreton: performing experiments, collection and assembly of data, data analysis and interpretation, manuscript writing

Charles H. Wassmer: collection of data, writing of manuscript

Kevin Bellofatto: collection of data, writing of manuscript

Lisa Perez: collection of data

Véronique Othenin-Girard: provision of study material or patients

Begoña Martinez de Tejada: provision of study material or patients

Marie Cohen: provision of study material or patients, manuscript writing

Ekaterine Berishvili: conception and design, financial support, data analysis and interpretation, manuscript writing, final approval of manuscript.

Acknowledgements

N/A

References

1. Vantyghem MC, de Koning EJP, Pattou F, Rickels MR. Advances in beta-cell replacement therapy for the treatment of type 1 diabetes. Lancet. 2019;394(10205):1274-85.
2. Delaune V, Berney T, Lacotte S, Toso C. Intraportal islet transplantation: the impact of the liver microenvironment. Transpl Int. 2017;30(3):227-38.

3. Kanak MA, Takita M, Kunnathodi F, Lawrence MC, Levy MF, Naziruddin B. Inflammatory response in islet transplantation. Int J Endocrinol. 2014;2014:451035.

4. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J Leukoc Biol. 2005;77(5):587-97.

5. Cieslak M, Wojtczak A, Cieslak M. Role of pro-inflammatory cytokines of pancreatic islets and prospects of elaboration of new methods for the diabetes treatment. Acta Biochim Pol. 2015;62(1):15-21.

6. Kaufman DB, Gores PF, Field MJ, Famey AC, Gruber SA, Stephanian E, et al. Effect of 15-deoxyspergualin on immediate function and long-term survival of transplanted islets in murine recipients of a marginal islet mass. Diabetes. 1994;43(6):778-83.

7. Citro A, Cantarelli E, Piemonti L. Anti-inflammatory strategies to enhance islet engraftment and survival. Curr Diab Rep. 2013;13(5):733-44.

8. Wassmer CH, Lebreton F, Bellofatto K, Bosco D, Berney T, Berishvili E. Generation of insulin-secreting organoids: a step toward engineering and transplanting the bioartificial pancreas. Transpl Int. 2020.

9. Arzouni AA, Vargas-Seymour A, Nardi N, A JFK, Jones PM. Using Mesenchymal Stromal Cells in Islet Transplantation. Stem Cells Transl Med. 2018;7(8):559-63.

10. Saeedi P, Halabian R, Imani Fooladi AA. A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies. Stem Cell Investig. 2019;6:34.

11. Hall B, Andreeff M, Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol. 2007(180):263-83.

12. Magatti M, Vertua E, Cargnoni A, Silini A, Parolini O. The Immunomodulatory Properties of Amniotic Cells: The Two Sides of the Coin. Cell Transplant. 2018;27(1):31-44.

13. Wassmer CH, Berishvili E. Immunomodulatory Properties of Amniotic Membrane Derivatives and Their Potential in Regenerative Medicine. Curr Diab Rep. 2020;20(8):31.

14. Miki T, Lehmann T, Cai H, Stolz DB, Strom SC. Stem cell characteristics of amniotic epithelial cells. Stem Cells. 2005;23(10):1549-59.

15. Ilancheran S, Michalska A, Peh G, Wallace EM, Pera M, Manuelpillai U. Stem cells derived from human fetal membranes display multilineage differentiation potential. Biol Reprod. 2007;77(3):577-88.

16. Banas RA, Trumpower C, Bentlejewski C, Marshall V, Sing G, Zeevi A. Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. Hum Immunol. 2008;69(6):321-8.

17. Keshavarzi B, Tabatabaei M, Zamani AH, Tehrani FR, Bozorgmehr M, Mosaffa N. The effect of human amniotic epithelial cell on dendritic cell differentiation of peripheral blood monocytes: An experimental study. Int J Reprod Biomed. 2020;18(6):449-64.
18. Harirah HM, Donia SE, Parkash V, Jones DC, Hsu CD. Localization of the Fas-Fas ligand system in human fetal membranes. J Reprod Med. 2002;47(8):611-6.

19. Lefebvre S, Adrian F, Moreau P, Gourand L, Dausset J, Berrih-Aknin S, et al. Modulation of HLA-G expression in human thymic and amniotic epithelial cells. Hum Immunol. 2000;61(11):1095-101.

20. Lebreton F, Bellofatto K, Wassmer CH, Perez L, Lavallard V, Pamaud G, et al. Shielding islets with human amniotic epithelial cells enhances islet engraftment and revascularization in a murine diabetes model. Am J Transplant. 2020.

21. Lebreton F, Lavallard V, Bellofatto K, Bonnet R, Kalandadze V, Wassmer CH, et al. Insulin-producing organoids engineered from islet- and amniotic epithelial cells to treat diabetes. Nature Communications. 2019;10.

22. Kakabadze Z, Gupta S, Brandhorst D, Korsgren O, Berishvili E. Long-term engraftment and function of transplanted pancreatic islets in vascularized segments of small intestine. Transpl Int. 2011;24(2):175-83.

23. Kakabadze Z, Gupta S, Pileggi A, Molano RD, Ricordi C, Shatirishvili G, et al. Correction of diabetes mellitus by transplanting minimal mass of syngeneic islets into vascularized small intestinal segment. Am J Transplant. 2013;13(10):2550-7.

24. Matsuda T, Omori K, Vuong T, Pascual M, Valiente L, Ferreri K, et al. Inhibition of p38 pathway suppresses human islet production of pro-inflammatory cytokines and improves islet graft function. Am J Transplant. 2005;5(3):484-93.

25. Lebreton F, Lavallard V, Bellofatto K, Bonnet R, Wassmer CH, Perez L, et al. Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes. Nature Communications. 2019;10(1):4491.

26. Qureshi KM, Lee J, Paget MB, Bailey CJ, Cumow SJ, Murray HE, et al. Low gravity rotational culture and the integration of immunomodulatory stem cells reduce human islet allo-reactivity. Clin Transplant. 2015;29(1):90-8.

27. Pires BRB, Silva R, Ferreira GM, Abdelhay E. NF-kappaB: Two Sides of the Same Coin. Genes (Basel). 2018;9(1).

28. Lindstrom TM, Bennett PR. The role of nuclear factor kappa B in human labour. Reproduction. 2005;130(5):569-81.

29. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3(3):221-7.

30. Yu Y, Wan Y, Huang* C. The Biological Functions of NF-κB1 (p50) and its Potential as an Anti-Cancer Target. Curr Cancer Drug Targets. 2009;9(4):566-71.

31. Rahmati M, Petitbarat M, Dubanchet S, Bensussan A, Chaouat G, Ledee N. Colony Stimulating Factors 1, 2, 3 and early pregnancy steps: from bench to bedside. J Reprod Immunol. 2015;109:1-6.

32. Gomez Y, Diaz-Solano D, Gledhill T, Wittig O, Cardier J. The effect of G-CSF and AMD3100 on mice treated with streptozotocin: Expansion of alpha-cells and partial islet protection. Cytokine. 2017;96:123-31.
33. Robertson SA. GM-CSF regulation of embryo development and pregnancy. Cytokine Growth Factor Rev. 2007;18(3-4):287-98.

34. Furmento VA, Marino J, Blank VC, Roguin LP. The granulocyte colony-stimulating factor (G-CSF) upregulates metalloproteinase-2 and VEGF through PI3K/Akt and Erk1/2 activation in human trophoblast Swan 71 cells. Placenta. 2014;35(11):937-46.

35. Martins A, Han J, Kim SO. The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis. IUBMB Life. 2010;62(8):611-7.

36. Zoso A, Serafini P, Lanzoni G, Peixoto E, Messinger S, Mantero A, et al. G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts. PLoS One. 2016;11(6):e0157245.

37. Gustafson KS, Ginder GD. Interferon-gamma induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1alpha to a distinct interferon-gamma-responsive element. J Biol Chem. 1996;271(33):20035-46.

38. Lefebvre S, Moreau P, Guiard V, Ibrahim EC, Adrian-Cabestre F, Menier C, et al. Molecular mechanisms controlling constitutive and IFN-gamma-inducible HLA-G expression in various cell types. J Reprod Immunol. 1999;43(2):213-24.

39. Castelli EC, Veiga-Castelli LC, Yaghi L, Moreau P, Donadi EA. Transcriptional and posttranscriptional regulations of the HLA-G gene. J Immunol Res. 2014;2014:734068.

40. Cnop M, Welsh N, Jonas JC, Joms A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54 Suppl 2:S97-107.

41. Farnsworth NL, Walter RL, Hemmati A, Westacott MJ, Benninger RK. Low Level Pro-inflammatory Cytokines Decrease Connexin36 Gap Junction Coupling in Mouse and Human Islets through Nitric Oxide-mediated Protein Kinase Cdelta. J Biol Chem. 2016;291(7):3184-96.

42. Ferreira LMR, Meissner TB, Tilburgs T, Strominger JL. HLA-G: At the Interface of Maternal-Fetal Tolerance. Trends Immunol. 2017;38(4):272-86.

43. Wieten L, Mahaweni NM, Voorter CE, Bos GM, Tilanus MG. Clinical and immunological significance of HLA-E in stem cell transplantation and cancer. Tissue Antigens. 2014;84(6):523-35.

44. Kim YH, Lim DG, Wee YM, Kim JH, Yun CO, Choi MY, et al. Viral IL-10 gene transfer prolongs rat islet allograft survival. Cell Transplant. 2008;17(6):609-18.

45. Vaithilingam V, Evans MDM, Lewy DM, Bean PA, Bal S, Tuch BE. Co-encapsulation and co-transplantation of mesenchymal stem cells reduces pericapsular fibrosis and improves encapsulated islet survival and function when allografted. Sci Rep. 2017;7(1):10059.

46. Choi SE, Choi KM, Yoon IH, Shin JY, Kim JS, Park WY, et al. IL-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transpl Immunol. 2004;13(1):43-53.

47. Marasco MR, Conteh AM, Reissaus CA, Cupit JEt, Appleman EM, Mirmira RG, et al. Interleukin-6 Reduces beta-Cell Oxidative Stress by Linking Autophagy With the Antioxidant Response. Diabetes.
48. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271(2):736-41.

49. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003;170(6):3369-76.

50. Norby K. Interleukin-8 and de novo mammalian angiogenesis. Cell Prolif. 1996;29(6):315-23.

Tables

Table 1: List of the genes evaluated for expression changes by RT-qPCR and associated primer sequences.
| Species | Gene | Forward sequence | Reverse sequence | Method |
|---------|------|------------------|------------------|--------|
| Human   | IL4  | ACT GCA CAG CAG TTC CAC AG | CTC TGG TTG GCT TCC TTC AC | SYBR   |
| Human   | IL6  | CAC ACA GAC AGC CAC TCA CC | TTT TCT GCC AGT GCC TCT TT | SYBR   |
| Human   | IL8  | GAT CCA CAA GCC TTG TTC | CGT AAT TCA ACA CAG CAC TAC | SYBR   |
| Human   | IL10 | AAG CCT GAC CAC GCT TTC TA | GCT CCC TGG TTT CTC TCC CT | SYBR   |
| Human   | HLA-G| TTG CTG GCC TGG TTG TCC TT | TTG CCA CTC AGT CCC ACA CAG | SYBR   |
| Human   | HLA-E| CCT ACG ACG GCA AGG A | CCC TTC TCC AGG TAT TTG TG | SYBR   |
| Human   | STAT1| TCC AGG AAG ACC CAA TCC AG | TGA ATA TCC CCC GAC TGA GC | SYBR   |
| Human   | STAT3| AGT GAG TAA GGC TGG GCA GA | AAG GCA CCC ACA GAA ACA AC | SYBR   |
| Human   | JAK1 | CGC TCT GGG AAA TCT GCT AC | AGG TCA GCC AGC TCC TTA CA | SYBR   |
| Human   | JAK2 | GAG CCT ATC GGC ATG GAA TA | TTA TCC ATC CGT GCA CAA AA | SYBR   |
| Human   | NFKB1| AAC AGA GAG GAT TTC GTT TCC G | TTT GAC CTG AGG GTA AGA CTT CT | SYBR   |
| Human   | RPLP0| AAG GTG TAA TCC GTC TCC ACA GA | TGC ATC AGT ACC CCA TCC TAT CAT | SYBR   |
| Human   | EIF2B1| CGG ACG TTG CTG GAG TTC TT | CCA CAC CAC ACA GGG TTT CT | SYBR   |
| Rat     | Nfkb1| GGG CTG ACC TGA GTC TTC TG | GAT AAG GAG TGC TGC CTT GC | SYBR   |
| Rat     | Rplp1| TCT CTG AGC TTG CCT GCA TCT ACT | CCT ACA TTG CAG ATG AGG CTT CCA | SYBR   |
| Rat     | Bcl2 | Rn99999125-m1 | Taqman |
| Rat     | Actb | Rn00667869-m1 | Taqman |

**Figures**

Page 18/25
Figure 1

Isolation and characterization of human amniotic epithelial cells (hAECs) A: Schematic representation of hAECs isolation protocol. Human amniotic membrane is harvested from term placenta, washed and hAECs are detached from the membrane using trypsin-EDTA. The resulting cells are then washed and cultured for 5-7 days. HAECs are then removed from the culture asks at 80% confluence by mild trypsinization, and cryopreserved for later use. B: hAECs were characterized by flow cytometry. Upper left
panel shows the gating strategy used to obtain the quantification of positive populations for mesenchymal markers (CD105, CD90), pluripotency marker (SSEA-4), epithelial marker (CD326) and immunomodulatory markers (HLA-E and HLA-G). Representative examples are shown in the right panel, and quantification from 28 distinct hAECs batches (i.e. isolated from 28 placentae) is shown in the bottom left panel. C: Immunofluorescent images of hAECs stained for the pluripotency markers SSEA-4 and Oct-4 and the immunomodulatory marker HLA-G (upper panels, scale bars = 100 um) and corresponding magnifications (lower panels, scale bars = 10 um).
IFN-γ increases the expression of HLA-E and HLA-G in hAECs. hAEC monocultures were exposed to various concentrations of IFN-γ for 24 and 48h and were characterized by flow cytometry. A: Representative flow cytometry histograms for CD105 (left panel), HLA-G (central panel) and HLA-E (right panel) positive populations in hAEC cultures exposed for 48h to 1000 U/mL IFN-γ (dark lines) compared to untreated hAECs (grey lines). Isotype control is shown as dotted lines. Positive population for HLA-G (B), HLA-E (C) and CD105 (D), were quantified after exposition to low (left panels: 10, 25 and 50 U/mL, n=4), medium (central panels: 100, 200 and 500 U/mL, n=2 for HLA-G quantification, n=4 for CD105 and HLA-E quantification) and high (right panels: 1000 and 2000 U/mL, n=3) concentrations of IFN-γ. Grey bars: 24h exposure, black bars: 48h exposure. * p<0.05, ** p<0.01, **** p<0.0001.
Figure 3

hAECs secrete anti-inflammatory cytokines under pro-inflammatory conditions and protect rat islets against proinflammatory cytokine-induced damages. A: Schematic representation of the experimental protocol. hAECs were cultured for 48h before being exposed to a pro-inflammatory cytokines cocktail (100 U/mL IFN-γ, 800 U/mL TNF-α, 50 u/mL IL-1β) for 48h. Rat islets (RI) were added 24h after hAEC seeding and were cultured on the hAEC monolayers for 24 hours before cytokines exposure. Controls...
were untreated and cytokines-exposed RI monocultures. B: IL6 (left), IL10 (central) and G-CSF (right) secretion quantifications in the hAEC culture supernatants before (n=4), after 24h (n=2) and 48h (n=4) of cytokines cocktail exposure. C. Expression changes in hAEC monocultures after cytokines cocktail exposure for anti-inflammatory cytokine genes (left), immunomodulatory genes (central) and IFN-γ signaling-related genes (right) (n=4). D. Apoptosis rate (i.e. relative quantification of cytoplasmic histone-associated DNA fragments) in RI and hAEC monocultures and in RI + hAECs co-cultures untreated or exposed to the cytokines cocktail for 48h (n=3). E. Expression changes in rat islets cultured alone or with hAECs after cytokines cocktail exposure for the pro-apoptotic Nfkb1 and the anti-apoptotic Bcl2 genes (n=4). F. Islet function given as the secretion index during a glucose stimulated insulin secretion test performed on RI cultured alone or with hAECs in the presence or absence of pro-inflammatory cytokines (n=3). Blue bars: Untreated cultures, red bars: cultures exposed to the cytokine cocktail. Empty bars: hAEC monocultures, patterned bars: RI monocultures, filled bars: RI+hAEC cocultures. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
Figure 4

Mechanisms behind immunomodulation and cytoprotection conferred to pancreatic islet by hAECs

Interrupted lines: Inhibitory or stimulatory cytokine-induced cascades leading to the improved immunomodulatory and anti-inflammatory properties of hAECs under pro-inflammatory conditions. Bold lines: Signaling pathways leading to proinflammatory cytokine induced islet β cell apoptosis and loss of function. Dotted lines: Signaling pathways triggered by the anti-inflammatory and immunomodulatory factors secreted by hAECs. Red color indicates inhibitory pathways whereas green indicates activating pathways.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- GraphicalAbstract.png